

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|

Lower Risk Higher Risk

JPMorgan Funds -

# Thematics - Genetic Therapies

Class: JPM Thematics - Genetic Therapies A (acc) - USD

## Fund overview

|  |                                   |  |
|--|-----------------------------------|--|
| <b>ISIN</b><br>LU2050612402  | <b>Valor</b><br>50072717          | <b>Bloomberg</b><br>JPGTAUA LX   |
| <b>Investment objective:</b> To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.  |                                   |  |
| <b>Investment approach</b>   |                                   |  |
| <ul style="list-style-type: none"> <li>• Uses the ThemeBot which, through natural language processing, determines textual relevance and revenue attribution to identify companies with the highest exposure to the theme.</li> <li>• Considers insights from a team of specialist sector analysts who review the ThemeBot's results to assess their appropriateness for the portfolio.</li> <li>• Determines the position sizes of the securities identified as having the highest exposure to the theme by taking into consideration not only textual relevance and revenue attribution but also their quality, liquidity and market capitalisation.</li> </ul> |                                   |  |
| <b>Portfolio manager(s)</b><br>Yazann Romahi<br>Aijaz Hussain  | <b>Share class currency</b> USD   | <b>Class launch</b><br>24 Oct 2019   |
| <b>Investment specialist(s)</b><br>Katherine Magee<br>Hanna Bach Nielsen   | <b>Fund assets</b><br>USD 757,6m  | <b>Domicile</b> Luxembourg   |
| <b>Fund reference currency</b> USD   | <b>NAV</b> USD 106,55             | <b>Entry/exit charges</b><br>Entry charge (max) 5,00%<br>Exit charge (max) 0,50% |
|  | <b>Fund launch</b><br>24 Oct 2019 | <b>Ongoing charge</b> 0,94%  |
| <b>ESG information</b>   |                                   |  |
| <b>ESG approach - Thematic</b><br>Investments in themes or assets specifically related to sustainability.  |                                   |  |
| <b>SFDR classification: Article 8</b><br>"Article 8" strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective.  |                                   |  |


## Fund ratings As at 31 March 2024

Morningstar Category™ Sector Equity Biotechnology

## Performance

- 1 **Class:** JPM Thematics - Genetic Therapies A (acc) - USD
- 2 **Benchmark:** MSCI All Country World Index (Total Return Net)

### Growth of USD 100,000 Calendar years



### Calendar Year Performance (%)

|   | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020  | 2021   | 2022   | 2023  |
|---|------|------|------|------|------|------|-------|--------|--------|-------|
| 1 | -    | -    | -    | -    | -    | -    | 45,74 | -12,76 | -29,55 | -3,47 |
| 2 | -    | -    | -    | -    | -    | -    | 16,25 | 18,54  | -18,36 | 22,20 |

### Return (%)

|   | Cumulative |          |        |      | Annualised |         |        |
|---|------------|----------|--------|------|------------|---------|--------|
|   | 1 month    | 3 months | 1 year | YTD  | 3 years    | 5 years | Launch |
| 1 | -2,87      | 4,35     | 5,20   | 4,35 | -12,82     | -       | 1,44   |
| 2 | 3,14       | 8,20     | 23,22  | 8,20 | 6,96       | -       | 11,02  |

### Performance Disclosures

**Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested.**

### ESG

For more information on environmental, social and governance (ESG) integration and our approach to sustainable investing at J.P. Morgan Asset Management please visit <https://am.jpmorgan.com/ch-en/esg>

## Portfolio analysis

| Measurement               | 3 years | 5 years |
|---------------------------|---------|---------|
| Correlation               | 0,65    | -       |
| Alpha (%)                 | -18,49  | -       |
| Beta                      | 0,87    | -       |
| Annualised volatility (%) | 21,78   | -       |
| Sharpe ratio              | -0,64   | -       |
| Tracking error (%)        | 16,60   | -       |
| Information ratio         | -1,16   | -       |

| Regions (%)                |      | Compared to benchmark |
|----------------------------|------|-----------------------|
| North America              | 78,3 | +11,7                 |
| Europe & Middle East ex UK | 9,1  | -2,9                  |
| Japan                      | 5,6  | +0,1                  |
| Emerging Markets           | 4,7  | -5,3                  |
| Pacific ex-Japan           | 1,9  | -0,6                  |
| United Kingdom             | 0,0  | -3,4                  |
| Cash                       | 0,4  | +0,4                  |

## Holdings

| Top 10<br>As at 29 February 2024 | Sector      | % of assets |
|----------------------------------|-------------|-------------|
| Krystal Biotech                  | Health Care | 3,5         |
| CRISPR Therapeutics              | Health Care | 3,2         |
| Iovance Biotherapeutics          | Health Care | 3,1         |
| Vertex Pharmaceuticals           | Health Care | 3,1         |
| Novartis                         | Health Care | 3,0         |
| Sarepta Therapeutics             | Health Care | 3,0         |
| Ionis Pharmaceuticals            | Health Care | 2,7         |
| Takeda Pharmaceutical            | Health Care | 2,7         |
| Biomarin                         | Health Care | 2,7         |
| Gilead Sciences                  | Health Care | 2,7         |

## Key risks

The Sub-Fund is subject to **Investment risks** and **Other associated risks** from the techniques and securities it uses to seek to achieve its objective.

The table on the right explains how these risks relate to each other and the **Outcomes to the Shareholder** that could affect an investment in the Sub-Fund.

Investors should also read [Risk Descriptions](#) in the Prospectus for a full description of each risk.

### Investment risks *Risks from the Sub-Fund's techniques and securities*

| Techniques    | Securities       |                   |
|---------------|------------------|-------------------|
| Concentration | Emerging markets | Smaller companies |
| Hedging       | Equities         |                   |
| Thematic      |                  |                   |

### Other associated risks *Further risks the Sub-Fund is exposed to from its use of the techniques and securities above*

| Currency | Liquidity | Market |
|----------|-----------|--------|
|          |           |        |

### Outcomes to the Shareholder *Potential impact of the risks above*

| Loss  | Volatility                                      | Failure to meet the Sub-Fund's objective. |
|---|---|---|
| Shareholders could lose some or all of their money. | Shares of the Sub-Fund will fluctuate in value. |   |

## General Disclosures

**This is a marketing communication.**

**Before investing, obtain and review the current prospectus (available in English), Key Information Document (KID) (available in English) and any applicable local offering document. These documents, as well as the sustainability-related disclosures, the annual and semi-annual reports and the articles of incorporation, are available free from your financial adviser, your J.P. Morgan Asset Management regional contact, the fund's issuer (see below) or at [www.jpmmam.ch](http://www.jpmmam.ch).**

A summary of investor rights is available in French at <https://am.jpmmam.com/ch-fr/droits-des-investisseurs>. J.P. Morgan Asset Management may decide to terminate the arrangements made for the marketing of its collective investment undertakings.

JPMorgan Asset Management (Switzerland) LLC herewith informs investors that with respect to its distribution activities in and from Switzerland it receives commissions pursuant to Art. 34 para. 2bis of the Swiss Collective Investment Schemes Ordinance dated 22 November 2006. These commissions are paid out of the management fee as defined in the fund documentation. Further information regarding these commissions, including their calculation method, may be obtained upon written request from JPMorgan Asset Management (Switzerland) LLC, Dreikönigstrasse 37, 8002 Zurich.

This material should not be considered as advice or an investment recommendation. Fund holdings and performance are likely to have changed since the report date.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our EMEA Privacy Policy [www.jpmmam.com/emea-privacy-policy](http://www.jpmmam.com/emea-privacy-policy)

For additional information on the sub-fund's target market please refer to the Prospectus.

**Risk Indicator** - The risk indicator assumes you keep the product for 5 year(s). The risk of the product may be significantly higher if held for less than the recommended holding period.

Current ongoing charge comprises annual management fee and operating & administrative expenses. Excludes transaction costs and may differ from ongoing costs as per KID which are an estimate based on the actual costs incurred over the past year.

## Performance information

Source: J.P. Morgan Asset Management. Share class performance is

shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees.

The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation.

Indices do not include fees or operating expenses and you cannot invest in them.

The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.

## Information Sources

Fund information, including performance calculations and other data, is provided by J.P. Morgan Asset Management (the marketing name for the asset management businesses of JPMorgan Chase & Co. and its affiliates worldwide).

**All data is as at the document date unless indicated otherwise.** © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Fund's Investment Objective and Policy.

Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

## Issuer

JPMorgan Asset Management (Europe) S.à r.l., 6, route de Trèves, L-2633 Senningerberg, Luxembourg. B27900, corporate capital EUR 10.000.000.

## FUNDS REPRESENTATIVE IN SWITZERLAND

JPMorgan Asset Management (Switzerland) LLC, Dreikönigstrasse 37, 8002 Zurich, Switzerland.

## FUNDS PAYING AGENT IN SWITZERLAND

J.P. Morgan (Suisse) SA, Rue du Rhône 35, 1204 Geneva, Switzerland.

## Contact in the UK:

JPMorgan Asset Management (UK) Limited Registered address: 25 Bank Street, Canary Wharf, London E14 5JP, United Kingdom. Authorised and regulated by the Financial Conduct Authority. Registered in England No. 01161446.

## Definitions

**NAV** Net Asset Value of a fund's assets less its liabilities per Share.

**Correlation** measures the strength and direction of the relationship between movements in fund and benchmark returns. A correlation of 1.00 indicates that fund and benchmark returns move in lockstep in the same direction.

**Alpha (%)** a measure of excess return generated by a manager compared to the benchmark. An alpha of 1.00 indicates that a fund has outperformed its benchmark by 1%.

**Beta** measures a fund's sensitivity to market movements (as represented by the fund's benchmark). A beta of 1.10 suggests the fund could perform 10% better than the benchmark in up markets and 10% worse in down markets, assuming all other factors remain constant. Usually the higher betas represent riskier investments.

**Annualised volatility (%)** measures the extent to which returns vary up and down over a given period.

**Sharpe ratio** performance of an investment adjusting for the amount of risk taken (compared a risk-free investment). The higher the Sharpe ratio the better the returns compared to the risk taken.

**Tracking error (%)** measures how much a fund's returns deviate from those of the benchmark. The lower the number the closer the fund's historic performance has followed its benchmark.

**Information ratio** measures if a manager is outperforming or

underperforming the benchmark and accounts for the risk taken to achieve the returns. A manager who outperforms a benchmark by 2%

p.a. will have a higher IR than a manager with the same outperformance but who takes more risk.